For research use only. Not for therapeutic Use.
LL1 is a novel potent and highly selective STAT3 inhibitor, displays anti-colorectal cancer activities in vitro and in vivo.
| Catalog Number | I030894 |
| Synonyms | LL1; LL 1; LL-1; |
| Molecular Formula | C20H18N4O3S |
| Purity | 98% |
| Solubility | Soluble in DMSO |
| Appearance | Solid powder |
| Storage | Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years). |
| IUPAC Name | 4-((2-(piperazin-1-yl)phenyl)amino)-5H-naphtho[1,8-cd]isothiazol-5-one 1,1-dioxide |
| InChI | InChI=1S/C20H18N4O3S/c25-20-13-4-3-7-18-19(13)15(23-28(18,26)27)12-16(20)22-14-5-1-2-6-17(14)24-10-8-21-9-11-24/h1-7,12,21-22H,8-11H2 |
| InChIKey | XSHDAFOFVMCVAM-UHFFFAOYSA-N |
| SMILES | O=S1(C2=CC=CC(C(C(NC3=CC=CC=C3N4CCNCC4)=C5)=O)=C2C5=N1)=O |
| Reference | 1: Liu Z, Wang H, Guan L, Lai C, Yu W, Lai M. LL1, a novel and highly selective STAT3 inhibitor, displays anti-colorectal cancer activities in vitro and in vivo. Br J Pharmacol. 2020 Jan;177(2):298-313. doi: 10.1111/bph.14863. Epub 2019 Nov 14. PMID: 31499589; PMCID: PMC6989959. |
